San Diego oncology diagnostics startup Epic Sciences has appointed Katherine Atkinson as its chief commercial officer. Atkinson was most recently vice president of business development at San Diego’s Edico Genome, which was acquired by Illumina (NASDAQ: [[ticker:ILMN]]) for $100 million in May. Prior to Edico Genome, Atkinson worked for Illumina. Previously Atkinson also had roles at Fisher Scientific, Thermo Fisher, and Beckman Coulter. Epic Sciences is developing blood tests to help clinicians determine the best cancer treatments.
Author: Sarah de Crescenzo
Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register.
She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine.
View all posts by Sarah de Crescenzo
